NeuroOne

NeuroOne occupies a focused position in neurosurgical medical devices, combining intracranial recording, stimulation, and ablation technologies rather than operating as a broad hospital-equipment manufacturer. Its portfolio includes the Evo sEEG Electrode, Evo Cortical Electrode, and OneRF Radiofrequency Ablation System. The central differentiator is the use of thin-film, high-definition electrodes designed for minimally invasive neurological procedures, including systems that can support both diagnostic and therapeutic workflows. OneRF is described as the first FDA 510(k)-cleared system using the same sEEG electrode for diagnostic and therapeutic applications, giving NeuroOne a product-level distinction in epilepsy care. The company is also extending the platform into trigeminal neuralgia, spinal cord stimulation, basivertebral nerve stimulation, and investigational drug delivery. Zimmer Biomet provides a commercial distribution channel for OneRF, separating NeuroOne from earlier-stage device developers that lack an established strategic distributor. However, NeuroOne remains a small public company with an employee range of approximately 11 to 50 people and an OTCQB listing.

NeuroOne's growth trajectory shows a transition from development-stage neurotechnology toward commercialization of a focused product platform. The company was founded in 2009 and became public on Dec 19, 2017. Its disclosed financing history includes 20 rounds and $64.3 million in total funding, with notable post-IPO equity raises of $12.5 million on Jan 12, 2021, $12.0 million on Oct 13, 2021, $5.25 million on Jul 25, 2023, and $8.0 million on Apr 4, 2025. A $10.5 million post-IPO debt round led by Zimmer Biomet in 2022 and a $3.0 million debt round led by Growth Opportunity Funding in 2024 added non-equity capital. Commercial inflection points include the limited OneRF launch in March 2024, the 2025 FDA submission for trigeminal-neuralgia treatment, and a limited release that treated 12 patients across three centers by March 2026. The company reported 105% year-over-year product-revenue growth in fiscal Q3 2025 and expected fiscal 2025 product revenue of $9.1 million. Its trajectory depends on converting thin-film electrode development into repeatable sales, expanding indications beyond epilepsy, and using Zimmer Biomet's distribution network to scale adoption.